Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide

about

Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.Metastatic melanoma to the brain: surgery and radiation is still the standard of care.

P2860

Q37579928-E4B94FE6-CD68-428F-898E-7F7EE23FCBA1 Q48121721-4AAA1FD7-C8C7-463C-A7E4-1EDBF5C1FC18

P2860

Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide

Item

http://www.wikidata.org/entity/Q38036217

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combining stereotactic radiosu ...... otential role for temozolomide

@en

type

Item

label

Combining stereotactic radiosu ...... otential role for temozolomide

@en

prefLabel

Combining stereotactic radiosu ...... otential role for temozolomide

@en

P1476

Combining stereotactic radiosu ...... otential role for temozolomide

@en

P2093

Matthew E Hardee

http://www.w3.org/2001/XMLSchema#string

Silvia C Formenti

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Stereotactic radiosurgery for four or more intracranial metastases.

Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life

A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.

Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.

Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2012.00099

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230712242

http://www.w3.org/2001/XMLSchema#string

P698

22908046

http://www.w3.org/2001/XMLSchema#string

P932

3414728

http://www.w3.org/2001/XMLSchema#string

Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide

about

P2860

P2860

Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932